SUBSCRIBE
SUBSCRIBE

Aspen Neuroscience

NEWS
Brain neurons synapse in human head isolated on black background, 3D rendering.
Parkinson’s disease
5 Investigational Therapies That Could Change the Parkinson’s Landscape
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
January 26, 2026
 · 
9 min read
 · 
Tristan Manalac
Pictured: A corporate building overlooking a freew
Money on the Move: SwanBio, Remix, Locus, Mirvie and More
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
May 18, 2022
 · 
8 min read
 · 
Hannah Chudleigh
Pictured: Financing concept/Getty Images
Business
Aspen Reels in $147.5M to Advance Personalized Parkinson’s Therapy
Aspen Neuroscience closed on a Series B funding round of $147.5 million. The company is focused on developing personalized cell replacements for Parkinson’s disease.
May 9, 2022
 · 
3 min read
 · 
Mark Terry
Look at these top life science startups.
Pharm Country
Top Life Science Startups to Watch in 2021
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
January 5, 2021
 · 
16 min read
 · 
Mark Terry
AWARDS
  • NextGen Class of 2021
JOBS
IN THE PRESS
Press Releases
Aspen Neuroscience Completes Phase 1/2a ASPIRO Trial Cohort Three Dosing and State-of-the-Art Manufacturing Expansion, Paving the Way for Developing Transformative Therapies for Patients
January 9, 2026
 · 
4 min read
Press Releases
Aspen Neuroscience Appoints Chief Commercial Officer Lisa Johnson-Pratt, M.D. and Welcomes Revati Shreeniwas, M.D., FCCP as Chief Medical Officer to Accelerate Late‑Stage Development and Commercial Readiness
January 8, 2026
 · 
4 min read
Press Releases
Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
November 21, 2025
 · 
4 min read
Press Releases
Aspen Neuroscience Initiates Cohort 3 in ASPIRO Phase 1/2a Trial, Highlighting Commercial Formulation of ANPD001 and Its Transformative Potential for Parkinson’s Disease
September 26, 2025
 · 
4 min read
Press Releases
Aspen Neuroscience to Present at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting
June 9, 2025
 · 
2 min read
Press Releases
Aspen Neuroscience to Present at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
May 14, 2025
 · 
2 min read
Press Releases
Aspen Neuroscience Announces 6-Month ASPIRO Phase 1/2a Clinical Trial Results of Personalized Cell Therapy for Parkinson’s Disease
May 8, 2025
 · 
5 min read
Press Releases
Aspen Neuroscience to Present at the International Society for Gene & Cell Therapy (ISCT) Annual Meeting
May 7, 2025
 · 
4 min read
Press Releases
Dalen Meeter Joins Aspen Neuroscience as Chief Financial Officer
May 1, 2025
 · 
2 min read
Press Releases
Aspen Neuroscience Announces Completion of First and Second Cohorts in ASPIRO Phase 1/2a Trial for Parkinson’s Disease
January 13, 2025
 · 
3 min read
Load More